Abstract:Purpose Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with low five-year survival rates. Currently, surgical resection is the only potentially curative treatment available to patients. However, few patients are eligible for surgery without receiving prior therapy due to disease progression. Of those that receive upfront surgery, up to 60% develop recurrent disease within 5 years. Therefore, there is a need to increase the rate of complete surgical resections and the number of eligible patients for surgery. In the last decade, neoadjuvant therapy or treatment prior to surgery has increased for patients diagnosed with borderline resectable and locally advanced PDAC. Often, this therapy consists of chemotherapy alone or chemoradiotherapy treatment intended to downstage the tumor and reduce micrometastatic disease. Fluorescence-guided surgery (FGS) is a potential tool to increase the rate of complete surgical resections by specifically targeting a protein biomarker upregulated in the tumor with a fluorescent dye conjugated probe. Previous in vitro and in vivo research from our lab has indicated that the transmembrane mucin, MUC16, is a promising target for FGS in PDAC. However, protein expression has the potential to deviate after chemotherapy treatment. Therefore, this research aimed to determine the effect of neoadjuvant chemotherapy treatment (NCT) on the FGS-targetable biomarker, MUC16, in PDAC patient specimens. Experimental Procedures Deidentified PDAC and matched adjacent patient specimens receiving the NCT regimen or surgery-first treatment were obtained from UNMC Pathology and the UNMC Paraffin Tissue Bank. Deidentified normal pancreas specimens were received from the Normal Organ Recovery program, UNMC. MUC16 expression was investigated in each specimen. The presence of PDAC tumor and MUC16 stain expression patterns were confirmed by a specimen-blinded, board-certified pathologist. The expression of MUC16 between the NCT, surgery-first, and normal pancreas specimens was compared via statistical analysis. Results MUC16 was expressed in both the NCT and surgery-first specimens. There was a significant difference in MUC16 expression between the NCT specimens and both the normal pancreas (P = 0.0450) and surgery-first (P = 0.0494) specimens. In matched adjacent tissue, MUC16 expression was found to be higher in the NCT (P = 0.0003) and surgery-first (P = 0.1446) tumor specimens allowing for distinct tumor margins; however, this difference was not significant in the surgery-first specimens. Conclusions MUC16 expression retention in NCT PDAC specimens may indicate that MUC16 is a stable biomarker after chemotherapy treatment. Distinct MUC16 expression between tumor and matched adjacent specimens indicates the ability to achieve distinguishable tumor margins allowing for complete tumor resection. Therefore, MUC16 remains targetable for FGS in chemotherapy-treated patients. This has the potential to broaden the benefiting patient population and increase the number of patients that may undergo a complete surgical resection. Citation Format: Kathryn M. Muilenburg, Evie G. Ehrhorn, Madeline T. Olson, Carly C. Isder, Kelsey A. Klute, Geoffrey A. Talmon, Mark A. Carlson, Quan P. Ly, Aaron M. Mohs. MUC16 expression in pancreatic ductal adenocarcinoma patient samples after neoadjuvant chemotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C008.

Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Data from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 4 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

The Clinical Utility of CA125/MUC16 in Pancreatic Cancer: A Consensus of Diagnostic, Prognostic and Predictive Updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

Supplementary Figure 2 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Single-cell Transcriptome Reveals the Heterogeneity of Malignant Ductal Cells and the Prognostic Value of REG4 and SPINK1 in Primary Pancreatic Ductal Adenocarcinoma

MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma

Additional File 29 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Abstract C008: MUC16 expression in pancreatic ductal adenocarcinoma patient samples after neoadjuvant chemotherapy

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma

Abstract A069: Study of MUC16/ERBB axis in pancreatic cancer

Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma

Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling

Additional File 28 of Proteogenomic Insights into the Biology and Treatment of Pancreatic Ductal Adenocarcinoma

Elevated Expression of Cell Adhesion, Metabolic, and Mucus Secretion Gene Clusters Associated with Tumorigenesis, Metastasis, and Poor Survival in Pancreatic Ductal Adenocarcinoma

Identification of Differentially Expressed Genes in Pancreatic Ductal Adenocarcinoma and Normal Pancreatic Tissues Based on Microarray Datasets.

Diagnostic and Prognostic Value of KRAS Mutations in Circulating Pancreatic Ductal Adenocarcinoma Tumor DNA

A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.